2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.33 Babu

PP01.33 Babu - Poster

Pdf Summary

A phase I study investigated the combination of ceritinib and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) negative for ALK rearrangement and EGFR mutation. The study aimed to determine the recommended phase 2 dose (RP2D) for the combination regimen. The results showed that the combination of docetaxel 75 mg/m2 IV every 3 weeks and ceritinib 150 mg PO daily was well-tolerated and showed preliminary evidence of clinical activity. However, the response rate and survival outcomes did not significantly differ from established docetaxel-based regimens. The study enrolled 21 patients, with median OS of 51.7 months for second-line treatment and 5.1 months for third-line and beyond. The overall response rate (ORR) was 14.3% and disease control rate (DCR) was 61.9%. The RP2D was determined based on tolerability and efficacy data, with consistent toxicity profile and no new safety signals identified. The study concluded that while there was some evidence of clinical activity, the outcomes did not show significant differences compared to standard docetaxel-based treatments. The study was funded by Novartis.

Keywords

ceritinib

docetaxel

non-small cell lung cancer

ALK rearrangement

EGFR mutation

recommended phase 2 dose

response rate

survival outcomes

overall response rate

disease control rate